CD151 and colorectal carcinoma: Using tetraspanin CD151 antibody-based immunohistochemistry, Lin et al. (16) found dynamic changes in the expression of this tetraspanin, observed in 48% of patients with early-stage CRC versus only 33% of patients with metastatic colon cancer [34].